Madrigal's Rezdiffra improves or stabilizes liver stiffness in up to 93% of patients in real-world studies

Bitget2026/11/05 15:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Madrigal Pharmaceuticals announced real-world Rezdiffra results presented at AASLD’s 2026 Liver Meeting for metabolic dysfunction-associated steatohepatitis.
Most patients showed improved or stable liver stiffness roughly one year into treatment, with additional improvements in liver fat and cardiometabolic markers.
Benefits were observed regardless of concurrent GLP-1 therapy, supporting use across patients with common metabolic conditions.
Most patients remained on treatment at one year, with high adherence among those continuing therapy.
Safety findings were consistent with clinical trials; reported treatment-related adverse events were infrequent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051000PRIMZONEFULLFEED9870944) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Madrigal's Rezdiffra improves or stabilizes liver stiffness in up to 93% of patients in real-world studies

You may also like

Crypto prices